These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 21155613

  • 1. Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study.
    Möricke R, Rettig K, Bethke TD.
    Clin Drug Investig; 2011; 31(2):87-99. PubMed ID: 21155613
    [Abstract] [Full Text] [Related]

  • 2. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
    Adis International Ltd.
    Drugs R D; 2003; 4(4):231-5. PubMed ID: 12848587
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
    Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA.
    Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
    [Abstract] [Full Text] [Related]

  • 4. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study Group.
    Ann Intern Med; 2007 Mar 06; 146(5):326-39. PubMed ID: 17339618
    [Abstract] [Full Text] [Related]

  • 5. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
    Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Liu ZM, Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC.
    Chin Med J (Engl); 2013 Feb 06; 126(3):457-63. PubMed ID: 23422107
    [Abstract] [Full Text] [Related]

  • 6. The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis.
    Zhang L, Yang M, Liu D, Guo C, Li L, Yang G.
    Exp Clin Endocrinol Diabetes; 2012 Jun 06; 120(6):361-6. PubMed ID: 22639400
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.
    Sturmer A, Mehta N, Giacchi J, Cagatay T, Tavakkol R, Mitta S, Fitzpatrick L, Wald J, Trang J, Stern W.
    Clin Pharmacokinet; 2013 Nov 06; 52(11):995-1004. PubMed ID: 23719683
    [Abstract] [Full Text] [Related]

  • 8. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD, Hanley DA, Lorraine JK, Yu M.
    Clin Ther; 2007 Sep 06; 29(9):2055-67. PubMed ID: 18035204
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
    Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP.
    Lancet Diabetes Endocrinol; 2013 Dec 06; 1(4):275-83. PubMed ID: 24622413
    [Abstract] [Full Text] [Related]

  • 10. Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis.
    Cipriani C, Pepe J, Silva BC, Rubin MR, Cusano NE, McMahon DJ, Nieddu L, Angelozzi M, Biamonte F, Diacinti D, Hans D, Minisola S, Bilezikian JP.
    J Bone Miner Res; 2018 Dec 06; 33(12):2132-2139. PubMed ID: 30088838
    [Abstract] [Full Text] [Related]

  • 11. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
    Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA.
    Osteoporos Int; 2013 Apr 06; 24(4):1503-11. PubMed ID: 22930240
    [Abstract] [Full Text] [Related]

  • 12. Recombinant full-length parathyroid hormone (1-84).
    Moen MD, Scott LJ.
    Drugs; 2006 Apr 06; 66(18):2371-81; discussion 2382-5. PubMed ID: 17181378
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C.
    Medicine (Baltimore); 2018 Nov 06; 97(47):e13341. PubMed ID: 30461654
    [Abstract] [Full Text] [Related]

  • 14. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
    Zhang XZ, Wang B, Yang J, Xuan M, Song LG, Li H, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Shen J, Liu ZM, Li CJ, Wu TF, Tong XC, Jia Y.
    Chin Med J (Engl); 2009 Dec 20; 122(24):2933-8. PubMed ID: 20137477
    [Abstract] [Full Text] [Related]

  • 15. The teriparatide in the treatment of severe senile osteoporosis.
    Manuele S, Sorbello L, Puglisi N, Grasso S, La Malfa L, D'Urbino G, Rizzotto M, Strano S, Maugeri D.
    Arch Gerontol Geriatr; 2007 Dec 20; 44 Suppl 1():249-58. PubMed ID: 17317460
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
    Lakatos P, Bajnok L, Lagast H, Valkusz Z.
    Endocr Pract; 2016 May 20; 22(5):523-32. PubMed ID: 26684150
    [Abstract] [Full Text] [Related]

  • 18. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 20; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 19. [A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China].
    Zhang XZ, Song LG, Wang B, Yang J, Li H, Xuan M, Lei T, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Shen J, Liu ZM, Li CJ, Wu TF, Xie HB, Tong JC.
    Zhonghua Nei Ke Za Zhi; 2010 Aug 20; 49(8):662-6. PubMed ID: 20979784
    [Abstract] [Full Text] [Related]

  • 20. The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis.
    Zhang L, Li L, Yang M, Xu K, Boden G, Yang G.
    Osteoporos Int; 2013 Mar 20; 24(3):1107-12. PubMed ID: 22419369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.